Super-ARMS^® EGFR Mutation Detection Kit

Currently there are several EGFR-TKIs approved for NSCLC (Non-small Cell Lung Cancer) targeted therapy including first-generation TKIs (gefitinib and erlotinib), second-generation TKI (afatinib) and third-generation TKI (osimertinib). To select right patients for these therapies, it is essential to detect EGFR mutation status before the treatment decision.

NSCLC tissue testing has been applied to EGFR mutation detection for years. However, up to 25% of patients with advanced or metastatic NSCLC do not have an available or sufficient tumor tissue sample for this method of testing. More and more dynamic monitoring demand for EGFR mutation status appears. When tissue sample is not a reliable or realistic option, the ctDNA (circulating tumor DNA) obtained from blood sample can be used for the assessment of EGFR mutation status.

Super-ARMS^® EGFR kit is a highly sensitive, real-time PCR-based test which is designed to identify ctDNA EGFR mutation in plasma samples for patients with advanced or metastatic NSCLC. The kit adopts innovative Super-ARMS^® technology which is upgraded from ADx-ARMS technology. Its optimized reaction system can rapidly and accurately detect low percentage of mutant ctDNA in a background of wild-type DNA.
 

Technological Principles:

The Super-ARMS^® EGFR mutation kit enables detection of the following 42 EGFR mutations:

• Exon 18: G719C, G719A, G719S

• Exon 19: 29 deletions

• Exon 20: T790M, S768I, 6 insertions

• Exon 21: L858R, L861Q

To order, please contact sales@amoydx.com.

* Li, Yuping, et al. "Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma." PloS one 12.8 (2017): e0183331.


Publications
1. Li, Yuping, et al. "Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma." PLoS One 12.8 (2017): e0183331.
2. Feng, Wei-neng, et al. "Comparison of the SuperARMS and Droplet Digital PCR for detecting EGFR mutation in ctDNA from NSCLC patients." Translational oncology 11.2 (2018): 542-545.
3. Cui, Shaohua, et al. "Use of superARMS EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma." Clinical lung cancer 19.3 (2018): e313-e322.
4. Wu, Wei, et al. "Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients." Diagnostic Pathology 15.1 (2020): 1-7.
5. Zhou, C., et al. "1331PDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms." Annals of Oncology 28.suppl_5 (2017).
6. Zhou, Yongchun, et al. "Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China." Scientific reports 8.1 (2018): 1-10.
7. Yang, Shuo, et al. "Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC." Lung Cancer 139 (2020): 133-139.
8. Finotti, Alessia, et al. "Liquid biopsy and PCR-free ultrasensitive detection systems in oncology." International journal of oncology 53.4 (2018): 1395-1434.
9. Linda, Č., et al. "Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma-Interlaboratory Quality Assessment in the Czech Republic." Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti 31.5 (2018): 353-360.
10. Gilson, Pauline. "Enrichment and Analysis of ctDNA." Tumor Liquid Biopsies. Springer, Cham, 2020. 181-211.